SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
18 avr. 2023 08h30 HE
|
SELLAS Life Sciences Group, Inc.
Next IDMC Meeting Scheduled for Q3 2023 REGAL on Track for Interim Analysis by Late 2023/Early 2024 NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS)...
SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
16 mars 2023 16h11 HE
|
SELLAS Life Sciences Group, Inc.
Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023/Early 2024 Ongoing Phase 1 Study of CDK9 Inhibitor Suggests Broad Therapeutic Window and High Potential for Both Monotherapy and...
SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
07 mars 2023 08h30 HE
|
SELLAS Life Sciences Group, Inc.
Safety and Immunogenicity Examined in Phase 1 Trial of GPS plus Anti–PD-1 Nivolumab in Patients with WT1-Expressing Relapsed Ovarian Cancer in the Post-Salvage Setting Immune Response Translated...
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering
24 févr. 2023 08h30 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Announces Proposed Underwritten Public Offering
23 févr. 2023 16h01 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
19 janv. 2023 08h30 HE
|
SELLAS Life Sciences Group, Inc.
Event will Feature Presentation from Hematology Oncology Expert Omer Jamy, MD, Phase 3 REGAL Study Principal Investigator at the University of Alabama Participating Site Webcast to be held on...
SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
05 janv. 2023 08h30 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies
13 déc. 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
GFH009 is First CDK9 Inhibitor Monotherapy to Achieve Compete Response in Acute Myeloid Leukemia Anticancer Effects Observed Across Multiple Dose Levels in Both Acute Myeloid Leukemia and Lymphoma...
SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
08 déc. 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute
06 déc. 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
Studies are Supported and Funded Through Cooperative Agreement Grants from the National Cancer Institute GFH009 to be Evaluated Against Pediatric Solid Tumors and Leukemia Models at Eight...